Latest Articles about XOMA

Positive Data on Celgene's Apremilast - Analyst Blog

Zacks Equity Research — Fri, 10 May 2013 00:23:59 Z

Celgene Corporation ( CELG ) recently announced positive results from the PALACE 4 study on apremilast. The study is evaluating apremilast (20 mg and 30 mg), a novel, oral small-molecule

Bayer Earnings Rise Y/Y - Analyst Blog

Zacks Equity Research — Sat, 27 Apr 2013 00:21:19 Z

Bayer 's ( BAYRY ) earnings during the first quarter of 2013 came in at €1.70 per share (approx. $2.24) compared with €1.67 per share (approx. $2.19) in the year-ago period. Earnings

AstraZeneca Earnings Tumble Y/Y - Analyst Blog

Zacks Equity Research — Fri, 26 Apr 2013 21:03:01 Z

AstraZeneca 's ( AZN ) first-quarter 2013 core earnings of $1.41 per American Depositary Share (ADS) beat the Zacks Consensus Estimate of $1.34. Earnings were down 21% (at constant

AZN/BIND Therapeutics Ink Deal - Analyst Blog

Zacks Equity Research — Wed, 24 Apr 2013 03:11:20 Z

AstraZeneca ( AZN ) recently announced that it has entered into an agreement with BIND Therapeutics for the development and commercialization of Accurin (a cancer nanomedicine). As per

Illumina Beats on Earnings, Revenue - Analyst Blog

Zacks Equity Research — Tue, 23 Apr 2013 23:11:11 Z

Illumina Inc.'s ( ILMN ) first-quarter 2013 adjusted earnings of 46 cents per share beat the Zacks Consensus Estimate by 21%. Adjusted earnings grew almost 28% over the prior-year quarter

AZN Inks Biomarker Discovery Deal - Analyst Blog

Zacks Equity Research — Fri, 19 Apr 2013 03:10:52 Z

AstraZeneca ( AZN ) recently announced that it has entered into an agreement with UK-based company, Oxford Cancer Biomarkers Ltd. As per the terms of the agreement, Oxford Cancer Biomarkers

Spectrum Progresses with SPI-2012 - Analyst Blog

Zacks Equity Research — Wed, 10 Apr 2013 01:09:49 Z

Spectrum Pharmaceuticals ( SPPI ) recently initiated a phase II study on SPI-2012 (LAPS-GCSF). SPI-2012 is being developed for the treatment of chemotherapy-induced neutropenia which

Illumina Introduces TruSight Tumor - Analyst Blog

Zacks Equity Research — Tue, 09 Apr 2013 02:10:51 Z

Recently, Illumina Inc. ( ILMN ) expanded its suite of TruSight content sets by adding TruSight Tumor to its portfolio. TruSight's content set is created according to different diseases.

Balanced View on Gilead Sciences - Analyst Blog

Zacks Equity Research — Fri, 29 Mar 2013 02:26:33 Z

On Mar 26, 2013, we reiterated our Neutral recommendation on Gilead Sciences, Inc. ( GILD ) as we believe that the stock is fairly priced at current levels with limited scope for upside.

More Protection for Biogen's Tecfidera - Analyst Blog

Zacks Equity Research — Fri, 22 Mar 2013 18:25:02 Z

Biogen Idec ( BIIB ) recently announced additional patent protection for its oral multiple sclerosis candidate, Tecfidera (dimethyl fumarate). The company said that the US Patent and

SGEN Seeks Adcetris Label Expansion - Analyst Blog

Zacks Equity Research — Wed, 20 Mar 2013 03:15:01 Z

Seattle Genetics, Inc. ( SGEN ) recently announced the submission of a supplemental biologics license application (sBLA) to the US Food and Drug Administration (FDA) for the use of Adcetris

XOMA Posts Narrower Loss - Analyst Blog

Zacks Equity Research — Thu, 14 Mar 2013 21:16:51 Z

XOMA Corporation ( XOMA ) reported fourth-quarter 2012 loss of 15 cents per share, narrower than the year-ago loss of 36 cents and the Zacks Consensus Estimate of a loss of 24 cents. Lower

Benzinga Market Primer: Tuesday, March 12

Matthew Kanterman — Tue, 12 Mar 2013 14:49:01 Z

Futures Slide on Asian Weakness U.S. equity futures slid in early pre-market trade after Asian shares reversed early gains to close lower. The Japanese Nikkei Index broke an eight-day winning

XOMA's Gevokizumab Study Update - Analyst Blog

Zacks Equity Research — Tue, 15 Jan 2013 03:11:01 Z

XOMA Corporation ( XOMA ) recently announced interim data from a phase II proof-of-concept (POC) study on gevokizumab, which is being developed for the treatment of inflammatory facial

XOMA Provides Update on Gevokizumab - Analyst Blog

Zacks Equity Research — Thu, 03 Jan 2013 00:45:01 Z

XOMA Corporation ( XOMA ) recently announced that it intends to include active non-infectious anterior scleritis in the gevokizumab proof-of-concept program. Non-infectious anterior